Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(33.3%)

Phase 4

3(33.3%)

Phase 1

2(22.2%)

Phase 3

1(11.1%)

9Total

Phase 2(3)

Phase 4(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05356143Phase 1Completed

A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

Role: lead

NCT00199238Phase 2Terminated

Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria

Role: lead

NCT00162786Phase 4Terminated

Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance

Role: lead

NCT00199264Phase 2Terminated

Efficacy Vulvovaginitis Candida

Role: lead

NCT00162799Phase 2Completed

Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

Role: lead

NCT00199251Phase 3Terminated

Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria

Role: lead

NCT00199225Phase 1Completed

Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers

Role: lead

NCT00258141Phase 4Unknown

Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects

Role: lead

NCT00199277Phase 4Unknown

Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.

Role: lead

All 9 trials loaded